(RTTNews) - ResMed Inc.(RMD), announced Thursday that its NightOwl home sleep apnea test or HSAT is now available across the United States, providing a simple and effective at-home diagnostic solution ...
SAN DIEGO, April 03, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced its home ...
SYDNEY, Feb 3 (Reuters) - Sleep-breathing device maker ResMed plans to take global a doctor education program aimed at promoting the screening of patients seeking Ozempic-style weight loss drugs for ...
A rival re-emerges, investors brace for impact and the Ozempic scare dissolves. ResMed’s growth story just got more interesting. ... Read More The post Dr Boreham’s Crucible: A rival may be circling, ...
(Reuters) - Medical equipment maker ResMed reported fourth-quarter revenue in line with estimates on Thursday, on steady demand for its sleep apnea treatment devices. The company's quarterly revenue ...
Jan 30 (Reuters) - ResMed (RMD.N), opens new tab beat Wall Street estimates for second-quarter profit on Thursday, driven by strong demand for its devices used to manage sleep apnea, a common sleep ...
ResMed is a dominant player in healthcare devices with strong margins, recurring revenues, and a near-monopoly, offering a compelling mix of value and growth. The company continually invests in R&D, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results